19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Antibodies are valuable molecules for the diagnostic and treatment of diseases caused by pathogens and toxins. Traditionally, these antibodies are generated by hybridoma technology. An alternative to hybridoma technology is the use of antibody phage display to generate recombinant antibodies. This in vitro technology circumvents the limitations of the immune system and allows—in theory—the generation of antibodies against all conceivable molecules. Phage display technology enables obtaining human antibodies from naïve antibody gene libraries when either patients are not available or immunization is not ethically feasible. On the other hand, if patients or immunized/infected animals are available, it is common to construct immune phage display libraries to select in vivo affinity‐matured antibodies. Because the phage packaged DNA sequence encoding the antibodies is directly available, the antibodies can be smoothly engineered according to the requirements of the final application. In this review, an overview of phage display derived recombinant antibodies against bacterial, viral, and eukaryotic pathogens as well as toxins for diagnostics and therapy is given.

          Related collections

          Most cited references256

          • Record: found
          • Abstract: found
          • Article: not found

          Aspergillus fumigatus and aspergillosis.

          J P Latgé (1999)
          Aspergillus fumigatus is one of the most ubiquitous of the airborne saprophytic fungi. Humans and animals constantly inhale numerous conidia of this fungus. The conidia are normally eliminated in the immunocompetent host by innate immune mechanisms, and aspergilloma and allergic bronchopulmonary aspergillosis, uncommon clinical syndromes, are the only infections observed in such hosts. Thus, A. fumigatus was considered for years to be a weak pathogen. With increases in the number of immunosuppressed patients, however, there has been a dramatic increase in severe and usually fatal invasive aspergillosis, now the most common mold infection worldwide. In this review, the focus is on the biology of A. fumigatus and the diseases it causes. Included are discussions of (i) genomic and molecular characterization of the organism, (ii) clinical and laboratory methods available for the diagnosis of aspergillosis in immunocompetent and immunocompromised hosts, (iii) identification of host and fungal factors that play a role in the establishment of the fungus in vivo, and (iv) problems associated with antifungal therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.

            G. Smith (1985)
            Foreign DNA fragments can be inserted into filamentous phage gene III to create a fusion protein with the foreign sequence in the middle. The fusion protein is incorporated into the virion, which retains infectivity and displays the foreign amino acids in immunologically accessible form. These "fusion phage" can be enriched more than 1000-fold over ordinary phage by affinity for antibody directed against the foreign sequence. Fusion phage may provide a simple way of cloning a gene when an antibody against the product of that gene is available.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Monoclonal antibody therapy of cancer.

              The most significant recent advances in the application of monoclonal antibodies (mAbs) to oncology have been the introduction and approval of bevacizumab (Avastin), an anti-vascular endothelial growth factor antibody, and of cetuximab (Erbitux), an anti-epidermal growth factor antibody. In combination with standard chemotherapy regimens, bevacizumab significantly prolongs the survival of patients with metastatic cancers of the colorectum, breast and lung. Cetuximab, used alone or with salvage chemotherapy, produces clinically meaningful anti-tumor responses in patients with chemotherapy-refractory cancers of the colon and rectum. In addition, the anti-HER2/neu antibody trastuzumab (Herceptin), in combination with standard adjuvant chemotherapy, has been shown to reduce relapses and prolong disease-free and overall survival in high-risk patients after definitive local therapy for breast cancer. These exciting recent results provide optimism for the development of mAbs that bind novel targets, exploit novel mechanisms of action or possess improved tumor targeting. Progress in the clinical use of radioimmunoconjugates remains hindered by complexity of administration, toxicity concerns and insufficiently selective tumor targeting.
                Bookmark

                Author and article information

                Contributors
                m.hust@tu-bs.de
                Journal
                Proteomics Clin Appl
                Proteomics Clin Appl
                10.1002/(ISSN)1862-8354
                PRCA
                Proteomics. Clinical Applications
                John Wiley and Sons Inc. (Hoboken )
                1862-8346
                1862-8354
                21 June 2016
                October 2016
                : 10
                : 9-10 , Pathoproteomics of Pathogenic Microorganisms ( doiID: 10.1002/prca.v10.9-10 )
                : 922-948
                Affiliations
                [ 1 ] Technische Universität Braunschweig Institut für Biochemie Biotechnologie und Bioinformatik Abteilung Biotechnologie Braunschweig Germany
                [ 2 ] YUMAB GmbH Braunschweig Germany
                Author notes
                [*] [* ] Correspondence: Dr. Michael Hust, Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Spielmannstr. 7, 38106 Braunschweig, Germany

                E‐mail: m.hust@ 123456tu-bs.de

                Article
                PRCA1770
                10.1002/prca.201600002
                7168043
                27198131
                7ab6cf52-bcff-47ee-ba02-870b30a4db69
                © 2016 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim

                This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

                History
                : 11 January 2016
                : 30 March 2016
                : 17 May 2016
                Page count
                Figures: 2, Tables: 4, Pages: 27, Words: 17865
                Funding
                Funded by: Eurostars
                Award ID: APTDETECT
                Funded by: Niedersachsen Vorab
                Award ID: VWZN2889
                Funded by: Conselho Nacional de Desenvolvimento Científico e Tecnológico , open-funder-registry 10.13039/501100003593;
                Award ID: PhD grant Gustavo Moreira
                Funded by: European Community's Seventh Framework Program (FP7/2007‐2013)
                Award ID: AntiBotABE 241832
                Categories
                Review
                Reviews
                Custom metadata
                2.0
                October 2016
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.0 mode:remove_FC converted:15.04.2020

                Molecular biology
                antibody phage display,antibody engineering,pathogens,toxins
                Molecular biology
                antibody phage display, antibody engineering, pathogens, toxins

                Comments

                Comment on this article